IRLA net incomeQ2 2026-$75.49M
IRLA net income was -$75.49M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$16.05M a year earlier. For the full fiscal 2025 it was -$83.98M, compared with -$56.83M in fiscal 2024.
IRulya Therapeutics Inc. (IRLA) financials
For the twelve months ended Jun 30, 2026, IRulya Therapeutics Inc. reported -$92.48M of net income.
- Net income, TTM
- -$92.48M
- Free cash flow, TTM
- -$47.00M
- Cash
- $115.98M
- Market cap
- $336.1M
FY2018FY2025
FY2018FY2025
IRLA revenue and earnings growth
IRLA EPSQ2 2026-$12.31
IRLA diluted EPS was -$12.31 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$16.80, compared with -$13.10 in fiscal 2024.
IRLA free cash flowQ2 2026-$18.89M
IRLA free cash flow was -$18.89M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.54M a year earlier. For the full fiscal 2025 it was -$41.78M, compared with -$32.16M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $35.38M | $18.59M | $9.45M | $25.18M | $60.80M | $61.31M | $30.21M | $10.09M |
| Selling, general and admin | $15.05M | $17.58M | $17.70M | $26.01M | $29.52M | $17.59M | $8.95M | $2.03M |
| Operating income | -$58.07M | -$57.28M | -$34.62M | -$52.02M | -$90.32M | -$78.89M | -$39.17M | -$12.12M |
| Interest expense | - | - | - | - | - | - | - | $957.0K |
| Pre-tax income | -$80.77M | -$56.74M | -$31.58M | -$51.94M | -$89.94M | -$76.85M | -$36.98M | - |
| Income tax | $3.21M | $87.0K | -$197.0K | -$284.0K | $0 | $0 | $0 | $0 |
| Net income | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -$89.94M | -$76.85M | -$36.98M | -$12.48M |
| EPS, basic | -$16.80 | -$13.10 | -$8.40 | -$15.40 | -$30.30 | -$26.30 | -$19.40 | -$37.10 |
| EPS, diluted | -$16.80 | -$13.10 | -$8.40 | -$15.40 | -$30.30 | -$26.30 | -$19.40 | -$37.10 |
| Diluted shares | 5.0M | 4.3M | 3.7M | 3.3M | 3.0M | 2.9M | 1.9M | 336,219.2 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.81M | $6.21M | $20.75M | $44.58M | $69.72M | $66.84M | $51.21M | $24.87M |
| Short-term investments | $11.94M | - | - | - | - | - | - | - |
| Receivables | - | - | - | $0 | - | - | - | - |
| Current assets | $22.90M | $44.04M | $77.44M | $93.75M | $111.67M | $137.86M | $106.06M | $72.58M |
| Goodwill | - | $0 | $17.63M | $0 | $0 | - | - | - |
| Total assets | $93.52M | $114.48M | $167.90M | $103.91M | $133.23M | $189.47M | $124.37M | $72.88M |
| Current liabilities | $43.23M | $7.28M | $9.57M | $3.07M | $14.22M | $17.00M | $8.89M | $1.46M |
| Short-term debt | $18.03M | $0 | - | - | - | - | - | - |
| Total debt | $0 | $14.32M | $13.43M | $0 | - | - | - | - |
| Total liabilities | $129.24M | $84.33M | $82.82M | $3.32M | $14.64M | $17.20M | $8.89M | $1.46M |
| Shareholders' equity | -$35.71M | $30.15M | $85.08M | $100.59M | $118.59M | $172.26M | $115.48M | -$32.63M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$41.42M | -$31.90M | -$18.29M | -$44.04M | -$62.93M | -$50.82M | -$33.28M | -$11.70M |
| Capital expenditures | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K |
| Free cash flow | -$41.78M | -$32.16M | -$18.45M | -$44.17M | -$63.11M | -$50.87M | -$33.33M | -$11.91M |
| Investing cash flow | $23.23M | $21.91M | -$5.76M | $18.00M | $58.95M | -$52.43M | -$17.75M | -$46.75M |
| Financing cash flow | $17.91M | -$4.78M | $143.0K | $707.0K | $6.81M | $118.88M | $77.37M | $75.93M |
| Stock-based compensation | $5.11M | $4.75M | $5.22M | $16.62M | $29.85M | $14.47M | $2.06M | $155.0K |
| Depreciation and amortization | $142.0K | $186.0K | $322.0K | $204.0K | $344.0K | $332.0K | $188.0K | $51.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | - | -188.5% | -36.9% | -51.4% | -75.8% | -44.6% | -32.0% | - |
| Return on assets | -89.8% | -49.6% | -18.7% | -49.7% | -67.5% | -40.6% | -29.7% | -17.1% |
| Current ratio | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 |
| Debt to equity | - | 0.48 | 0.16 | 0.00 | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $5.46M | $6.84M | $12.60M | $8.08M | $6.55M | $8.14M | $5.83M | $4.92M | $4.15M | $3.70M | $3.43M | $1.43M |
| Selling, general and admin | $16.63M | $4.27M | $3.63M | $3.28M | $3.34M | $4.79M | $4.28M | $3.63M | $4.70M | $4.97M | $4.91M | $4.66M |
| Operating income | -$79.78M | -$14.59M | -$19.35M | -$13.43M | -$10.43M | -$14.86M | -$12.01M | -$5.86M | -$28.19M | -$11.22M | -$9.92M | -$6.09M |
| Pre-tax income | - | - | - | - | - | -$14.98M | - | - | - | -$11.12M | - | - |
| Income tax | $75.0K | -$5.34M | $3.15M | -$46.0K | $67.0K | $47.0K | $7.0K | $13.0K | $36.0K | $31.0K | $51.0K | $0 |
| Net income | -$75.49M | $35.91M | -$39.46M | -$13.44M | -$16.05M | -$15.03M | -$12.46M | -$5.49M | -$27.73M | -$11.15M | -$8.89M | -$5.35M |
| EPS, basic | -$12.31 | $3.60 | - | -$2.50 | -$68.75 | -$3.42 | -$2.80 | -$1.30 | -$6.40 | -$2.60 | -$2.10 | -$1.50 |
| EPS, diluted | -$12.31 | $2.88 | - | -$2.50 | -$68.75 | -$3.42 | -$2.80 | -$1.30 | -$6.40 | -$2.60 | -$2.10 | -$1.50 |
| Diluted shares | 6.1M | 9.2M | - | 5.4M | 233,431 | 4.4M | - | 4.3M | 4.3M | 4.3M | - | 3.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $115.98M | $18.16M | $5.81M | $6.45M | $16.83M | $7.77M | $6.21M | $2.67M | $7.89M | $21.81M | $20.75M | $21.63M |
| Short-term investments | $0 | $0 | $11.94M | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | $500.0K |
| Current assets | $123.41M | $25.58M | $22.90M | $29.20M | $37.34M | $33.83M | $44.04M | $51.72M | $63.44M | $70.44M | $77.44M | $85.17M |
| Goodwill | - | - | - | $0 | - | - | $0 | $0 | $0 | $17.25M | $17.63M | $0 |
| Total assets | $124.00M | $26.62M | $93.52M | $109.90M | $117.21M | $107.09M | $114.48M | $126.52M | $134.83M | $159.29M | $167.90M | $85.39M |
| Current liabilities | $8.50M | $8.77M | $43.23M | $26.04M | $7.47M | $8.36M | $7.28M | $5.42M | $10.32M | $9.84M | $9.57M | $2.25M |
| Short-term debt | $0 | $0 | $18.03M | $17.52M | - | - | $0 | - | - | - | - | - |
| Total debt | - | - | $0 | $0 | $16.99M | $15.27M | $14.32M | $14.90M | $13.83M | $13.52M | $13.43M | - |
| Total liabilities | $15.51M | $10.95M | $129.24M | $108.84M | $105.47M | $88.51M | $84.33M | $81.59M | $87.86M | $85.11M | $82.82M | $2.25M |
| Shareholders' equity | -$35.32M | $15.67M | -$35.71M | $1.06M | $11.74M | $18.58M | $30.15M | $44.93M | $46.97M | $74.18M | $85.08M | $83.13M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.89M | -$7.63M | -$10.48M | -$9.93M | -$11.41M | -$9.60M | -$7.55M | -$7.26M | -$8.74M | -$8.35M | -$6.08M | -$4.82M |
| Capital expenditures | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K | $39.0K | $39.0K | $24.0K | $0 |
| Free cash flow | -$18.89M | -$7.63M | -$10.48M | -$10.00M | -$11.54M | -$9.75M | -$7.68M | -$7.31M | -$8.78M | -$8.39M | -$6.10M | -$4.82M |
| Investing cash flow | $8.00M | $12.00M | $8.07M | -$1.78M | $6.04M | $10.90M | $10.87M | $7.11M | -$4.98M | $8.91M | $5.39M | $3.63M |
| Financing cash flow | $108.93M | $9.44M | $2.03M | $1.38M | $14.41M | $87.0K | $0 | -$5.00M | $35.0K | $190.0K | $57.0K | $10.0K |
| Stock-based compensation | $12.09M | $1.29M | $1.19M | $1.25M | $1.27M | $1.39M | $1.13M | $1.12M | $1.22M | $1.27M | $1.09M | $1.33M |
| Depreciation and amortization | $41.0K | $36.0K | $39.0K | $36.0K | $35.0K | $32.0K | $16.0K | $86.0K | $44.0K | $40.0K | $304.0K | $0 |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 14.52 | 2.92 | 0.53 | 1.12 | 5.00 | 4.05 | 6.05 | 9.53 | 6.15 | 7.16 | 8.09 | 37.80 |
| Debt to equity | - | - | - | 0.00 | 1.45 | 0.82 | 0.48 | 0.33 | 0.29 | 0.18 | 0.16 | - |
Source: XBRL data IRulya Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported May 11, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IRLA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IRLA | - | - | -$92.48M | - | $336.1M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
IRLA FAQ
5 questionsIs IRLA profitable?
No. IRulya Therapeutics Inc. reported a net loss of $92.48M for the twelve months ended Jun 30, 2026.How much cash and debt does IRLA have?
IRulya Therapeutics Inc. reported $115.98M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is IRLA free cash flow?
IRulya Therapeutics Inc. generated -$47.00M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$46.92M less capital expenditures.When did IRLA last report financial results?
The latest statements here come from IRulya Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this IRLA financial data come from?
Quantisnow builds these statements from the structured XBRL data IRulya Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.